Design and Synthesis of Disodium Phosphate Derivatives of Norcantharidin

Abstract

Abstract: Aim To design and synthesize norcantharidin disodium phosphate derivatives. Methods Diels-Alder reaction between furan and maleic anhydride afforded dehydronorcantharidin, and subsequent hydrogenation, phosphorylation, and basification gave compounds 1 and 2, separately. Results The structures of compounds were confirmed by IR, NMR and FAB-MS. The aqueous solubility of 1 and 2 were improved, compared with the parent compounds, and their activities were more potent than norcantharidin 4 against MGC803 cell lines. Conclusion The phosphorylation of norcantharidin analogues is an effective way to increase the activity and solubility.

Key words: norcantharidin, norcantharidin, disodium phosphate, disodium phosphate, design, design, synthesis, synthesis

CLC Number:

R916.4

R916.696

Supporting:

ZHOU Yue, CAI Yu-chen, ZHANG Xue-jing, WANG Zhi-xin, XIAN Li-jian, ZOU Yong*. Design and Synthesis of Disodium Phosphate Derivatives of Norcantharidin[J]. .

References

[1] McCluskey A. Serine-threonine protein phosphatase inhibitors: development of protein therapeutic strategies [J]. J Med Chem , 2002, 45 (6) : 1151-1175.
[2] McCluskey A, Walkom C, BowyerMC, et al. Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines [J]. Bioorg Chem, 2003, 31 (1) : 68-79.
[3] McCluskey A, Walkom C, Bowyer MC, et al. Canthrimides: a new class of modified cantharidin analogues inhibiting protein phosphatases1 and 2A [J]. Bioorg Med Chem Lett, 2001, 11 (22) : 2941-2946.
[4] McCluskey A, Bowyer MC, Collins E, et al. Anhydride modified cantharidin analogues: synthesis, inhitition of protein phosphatases1 and 2A and anticancer activity [J]. Bioorg Med Chem Lett, 2000, 10 (15) : 1687-1690.
[5] Ho YP, To KK, Au-Yueng SC, et al. Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinesemedicine, with a platinum moiety [J]. J Med Chem, 2001, 44 (13) : 2065-2068.
[6] To KK, Ho YP, Au-Yueng SC, et al. Synergistic interaction between platinum-based antitumor agents and demethylcantharidin [J]. Cancer Lett, 2005, 223 (2) : 227-237.
[7] Fujii K, Maki K, Kanai M, et al. Formal catalytic asymmetric total synthesis of fostriecin [J]. Org Lett, 2003, 5 (5) : 733-736.
[8] Matsunaga S, Fujiki H, Sakada T. Calyculins E, F, G, and H, additional inhibitors of protein phosphatases 1 and 2a, from the marine sponge discodermia calyx [J]. Tetrahedron, 1991, 47 (18-19) : 2999.
[9] Stevenson JP, Rosen M, Sun W, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5 d schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow [J] J Clin Oncol, 2003, 21 (23) : 4428-4438.
[10] Hillery A, Lopez J. Anti-vascular targeting: a novel approach to cancer treatment [J]. PSTT, 2000, 3 (1) : 4.
[11] Griggs J , Skepper JN, Smith GA, et al. Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4 [J]. Am J Pathol, 2002, 160 (3) : 1097-1103.
[12] Pettit GR, Rhodes MR. antineop lastic Agents 389: new synthesis of the combretastatin A-4 prodrug [J]. Anti Cancer Drug Design, 1998, 13 (3) : 183-191.
[13] Pettit GR. Combretastatin A-1 phosphate and combretastatin B-1 phosphate prodrugs [P].US Pat: 0220298, 2003-11-27.
[14] CA 1956, 50: 13094i.
[15] Eggelte TA, Koning H, Huisman HO. Synhesis and some reductions of endo-and exo-3,6-epoxy-∆⁴-tetrahydrophthalic anhydride [J]. Tetrahedron, 1973, 29 (16) : 2445-2447.
[16] Liu FL, Jiang T, Zuo DS, et al. Synthesis of 5, 6-dihydronorcantharidin derivatives of substituted aromatic amine and their anti-tumor activities [J]. Chin J Org Chem , 2002, 22 (10) : 761-767.